| Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin Svensson, Ashton British journal of clinical pharmacology 48 (4), 528-535, 1999 | 239 | 1999 |
| In vivo blood-brain barrier transport of oxycodone in the rat: indications for active influx and implications for pharmacokinetics/pharmacodynamics E Boström, USH Simonsson, M Hammarlund-Udenaes Drug metabolism and disposition 34 (9), 1624-1631, 2006 | 238 | 2006 |
| Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption JJ Wilkins, RM Savic, MO Karlsson, G Langdon, H McIlleron, G Pillai, ... Antimicrobial agents and chemotherapy 52 (6), 2138-2148, 2008 | 200 | 2008 |
| Blood–brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine E Boström, M Hammarlund-Udenaes, USH Simonsson Anesthesiology: The Journal of the American Society of Anesthesiologists 108 …, 2008 | 170 | 2008 |
| An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations HE Silber, PM Jauslin, N Frey, R Gieschke, USH Simonsson, ... The Journal of Clinical Pharmacology 47 (9), 1159-1171, 2007 | 150 | 2007 |
| Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients JJ Wilkins, G Langdon, H McIlleron, G Pillai, PJ Smith, USH Simonsson British journal of clinical pharmacology 72 (1), 51-62, 2011 | 137 | 2011 |
| A population pharmacokinetic model incorporating saturable pharmacokinetics and autoinduction for high rifampicin doses RJ Svensson, RE Aarnoutse, AH Diacon, R Dawson, SH Gillespie, ... Clinical Pharmacology & Therapeutics 103 (4), 674-683, 2018 | 135 | 2018 |
| A general pharmacodynamic interaction model identifies perpetrators and victims in drug interactions SG Wicha, C Chen, O Clewe, USH Simonsson Nature communications 8 (1), 1-11, 2017 | 126 | 2017 |
| Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9 USH Simonsson, B Jansson, TN Hai, DX Huong, G Tybring, M Ashton Clinical Pharmacology & Therapeutics 74 (1), 32-43, 2003 | 125 | 2003 |
| A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients W Smythe, A Khandelwal, C Merle, R Rustomjee, M Gninafon, MB Lo, ... Antimicrobial agents and chemotherapy 56 (4), 2091-2098, 2012 | 117 | 2012 |
| Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients JJ Wilkins, G Langdon, H McIlleron, GC Pillai, PJ Smith, USH Simonsson European journal of clinical pharmacology 62 (9), 727-735, 2006 | 106 | 2006 |
| An integrated glucose‐insulin model to describe oral glucose tolerance test data in type 2 diabetics PM Jauslin, HE Silber, N Frey, R Gieschke, USH Simonsson, K Jorga, ... The Journal of Clinical Pharmacology 47 (10), 1244-1255, 2007 | 105 | 2007 |
| Artemisinin induces omeprazole metabolism in human beings USH Svensson, M Ashton, TN Hai, L Bertilsson, DX Huong, N Van Huong, ... Clinical Pharmacology & Therapeutics 64 (2), 160-167, 1998 | 104 | 1998 |
| Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833 E Boström, USH Simonsson, M Hammarlund-Udenaes Journal of pharmaceutical sciences 94 (5), 1060-1066, 2005 | 103 | 2005 |
| The potential for treatment shortening with higher rifampicin doses: relating drug exposure to treatment response in patients with pulmonary tuberculosis EM Svensson, RJ Svensson, LHM Te Brake, MJ Boeree, N Heinrich, ... Clinical Infectious Diseases 67 (1), 34-41, 2018 | 100 | 2018 |
| Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects S Asimus, D Elsherbiny, TN Hai, B Jansson, NV Huong, MG Petzold, ... Fundamental & clinical pharmacology 21 (3), 307-316, 2007 | 93 | 2007 |
| Population pharmacokinetics of ethambutol in South African tuberculosis patients S Jönsson, A Davidse, J Wilkins, JS Van der Walt, USH Simonsson, ... Antimicrobial agents and chemotherapy 55 (9), 4230-4237, 2011 | 86 | 2011 |
| High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glycoprotein involvement USH Svensson, R Sandström, Ö Carlborg, H Lennernäs, M Ashton Drug metabolism and disposition 27 (2), 227-232, 1999 | 84 | 1999 |
| Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults O Østerberg, RM Savic, MO Karlsson, USH Simonsson, JP Nørgaard, ... The Journal of Clinical Pharmacology 46 (10), 1204-1211, 2006 | 82 | 2006 |
| Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses SP Zvada, P Denti, PR Donald, HS Schaaf, S Thee, JA Seddon, HI Seifart, ... Journal of Antimicrobial Chemotherapy 69 (5), 1339-1349, 2014 | 77 | 2014 |
Helen McIlleronEmail confirmado em uct.ac.za
